Sève et al. [18, 19] conducted a retrospective study to explore the potential of this biomarker as a prognostic or predictive factor in advanced NSCLC patients and provided strong evidence that the overexpression of TUBB3 has a predictive value for paclitaxel therapy but is not itself a prognostic factor. The gene discussed is TUBB3; the disease is non-small cell lung carcinoma.